Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice

Biochemical Pharmacology

Volumn 80, Issue 3, 2010, Pages 352-361

  Lee, Ji Won ^a,d   Kobayashi, Yasuhiro ^a   Nakamichi, Yuko ^a   Udagawa, Nobuyuki ^a   Takahashi, Naoyuki ^a   Im, Nam Kyung ^b   Seo, Hwa Jeong ^b,c   Jeon, Won Bae ^c   Yonezawa, Takayuki ^d   Cha, Byung Yoon ^d   Woo, Je Tae ^d  

^a MATSUMOTO DENTAL UNIVERSITY   (Japan)

^b Keimyung University   (South Korea)

^c Daegu Gyeongbuk Institute of Science and Technology   (South Korea)

^d CHUBU UNIVERSITY   (Japan)

Author keywords

Alisol B; Anti resorptive agent; JNK; Osteoclast; RANKL

Indexed keywords

2 METHYLENE 19 NORCALCITRIOL; ACTIN; ALISOL B; CALCITRIOL; CALCITRIOL DERIVATIVE; COLONY STIMULATING FACTOR 1; JANUS KINASE; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PHYTOSTEROID; PROTEIN C FOS; PROTEIN NFATC1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STEROID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALISMA; ALISMA ORIENTALE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; UPREGULATION;

ANIMALS; BONE RESORPTION; CHOLESTENONES; COCULTURE TECHNIQUES; HUMANS; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; STEROIDS;

EID: 77953479142     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.014     Document Type: Article

References (62)

1. Suda T., Takahashi N., Martin T.J. Modulation of osteoclast differentiation. Endocr Rev 1991, 13:66-80.
2. Roodman G.D. Cell biology of the osteoclast. Exp Hematol 1999, 27:1229-1241.
3. Teitlebaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
4. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J Pathol 2000, 192:4-13.
5. Martin T.J., Romas E., Gillespie M.T. Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr 1998, 8:107-123.
6. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:1651-1676.
7. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
8. Darnay B.G., Aggarwal B.B. Signal transduction by tumor necrosis factor and tumor necrosis factor related ligands and their receptors. Ann Rheum Dis 1999, 58(Suppl. 1):I2-I13.
9. Darnay B.G., Haridas V., Ni J., Moore P.A., Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-κB (RANK): interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 1998, 273:20551-20555.
10. Wong B.R., Josein R., Lee S.Y., Vologodskaia M., Steinman R.M., Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 1998, 273:28355-28359.
11. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
12. Lerner U.H. New molecules in the tumor necrosis factor ligand and receptor super families with importance for physiological and pathological bone resorption. Crit Rev Oral Biol Med 2004, 15:64-81.
13. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638-649.
14. Koga T., Inuli M., Inoue K., Kim S., Suematsu A., Kobayashi E., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
15. Mócasi A., Humphrey M.B., van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004, 101:6158-6163.
16. Xiu R.J. Microcirculation and traditional Chinese medicine. J Am Med Assoc 1988, 269:1755-1757.
17. Koyama T. Osteoporosis with kampo treatment. Sanfujinka Chiryo 1991, 63:203-207.
18. Huang Y.T., Huang D.M., Chueh S.C., Teng C.M., Guh J.H. Alisol-B acetate, a triterpene from Alisma rhizome, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells. Cancer Lett 2006, 231:270-278.
19. Chen H.W., Hsu M.J., Chien C.T., Huang H.C. Effect of alisol B acetate, a plant triterpene, on apoptosis in vascular smooth muscle cells and lymphocytes. Eur J Pharmacol 2001, 419:127-138.
20. Xu Y.H., Zhao L.J., Li Y. Alisol-B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases/Akt signaling pathways. World J Gastroenterol 2009, 15:2870-2877.
21. Matsuda H., Kageura T., Toguchida I., Murakami T., Kishi A., Yoshikawa M. Effect of sesquiterpenes and triterpenes from the rhizome of Alisma orientale on nitric oxide production in lipopolysaccharide-activated macrophages: absolute sterostructures of alismaketones-B 23-acetate and -C 23-acetate. Bioorg Med Chem Lett 1999, 9:3081-3086.
22. Lee S.M., Kim J.H., Zhang Y., An R.B., Min B.S., Joung H., et al. Anti-complementary activity of protostane-type triterpenes from Alisma rhizome. Arch Pharm Res 2003, 26:463-465.
23. Kubo M., Matsuda H., Tomohiro N., Yoshikawa M. Studies on Alisma rhizome. I. Anti-allergic effects of methanol extract and six terpene components from Alisma rhizome (dried rhizome of Alisma orientale). Biol Pharm Bull 1997, 20:511-516.
24. Chapter 18: Generation of osteoclasts in vitro, and assay of osteoclast activity. In: A.P. Cope, editor. Arthritis research, vol. 1. Methods in molecular medicine, vol. 135. Totowa, NJ: Humana Press Inc. p. 291, 2007.
25. 3 in osteoclast differentiation and function. Methods Enzymol 1997, 282:223-235.
26. Okumura S., Mizoguchi T., Sato N., Yamaki M., Kobayashi Y., Yamaguchi H., et al. Coordination of microtubules and the actin cytoskeleton is important in osteoclast function, but calcitonin disrupts sealing zones without affecting microtubule networks. Bone 2006, 39:684-693.
27. Sato N., Takahashi N., Suda K., Nakamura M., Yamaki M., Ninomiya T., et al. MyD88 but not TRIF is essential for osteoclatogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1α. J Exp Med 2004, 200:601-611.
28. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003, 144:5441-5449.
29. Teitelbaum S.L. RANKing c-Jun in osteoclast development. J Clin Invest 2004, 114:463-465.
30. 3 with two substituents at C-2: synthesis and biological activity. Bioorg Med Chem Lett 2005, 15:1451-1455.
31. 3 analogs strongly stimulate osteoclast formation both in vivo and in vitro. Bone 2007, 40:293-304.
32. Phillipson J.D., Anderson L.A. Ethnopharmacology and western medicine. J Ethnopharmacol 1989, 25:61-72.
33. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclasts differentiation and activation. Nature 2003, 423:337-342.
34. Suda T. Modulation of osteoclasts differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
35. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Gene Dev 1999, 13:2412-2424.
36. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastofenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
37. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
38. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24:33-63.
39. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005, 83:170-179.
40. Takayanagi H. induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
41. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269.
42. Ikeda F., Nishimura R., Matsubara T., Tanaka S., Inoue J., Reddy S.V., et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004, 114:475-484.
43. Kim K., Kim J.H., Lee J., Jin H.M., Lee S.H., Fisher D.E., et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 2005, 208:35209-35216.
44. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., et al. Essential role of p38 mitogene-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279:45969-45979.
45. Sharma S.M., Bronisz A., Hu R., Patel K., Mansky K.C., Sif S., et al. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem 2007, 282:15921-15929.
46. Chang E.J., Kim H.J., Ha J., Kim H.J., Ryu J., Park K.H., et al. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci 2007, 120:166-176.
47. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-fos. J Biol Chem 2004, 279:26475-26480.
48. Vaannen H.K., Horton M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995, 108:2729-2732.
49. Suda T., Nakamura I., Jimi B., Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997, 12:869-879.
50. Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999, 145:527-538.
51. Lee S., Kho Y., Min B., Kim J., Na M., Kang S., et al. Cytotoxic triterpenoides from Alismatis Rhizoma. Arch Pharm Res 2001, 24:524-526.
52. Chou C.C., Pan S.L., Teng C.M., Guh J.H. Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells. Eur J Pharm Sci 2003, 19:403-412.
53. DeLuca H.F. The transformation of a vitamin into a hormone: the vitamin D story. Harvey Lect 1979-1980, 75:333-379.
54. Lamm M., Neuman W.F. On the role of vitamin D in calcification. AMA Arch Pathol 1958, 66:204-209.
55. 3: nuclear receptor structure and ligand specificities or genomic and rapid biological responses 2002, 545-571. Academic Press, New York. 2nd ed. J.P. Bilezikian, L.G. Raisz (Eds.).
56. Sicinski R.R., Prahl J.M., Smith C.M., DeLuca H.F. New 1α,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem 1998, 41:4662-4674.
57. Yamamoto H., Shevde N.K., Warrier A., Plum L.A., DeLuca H.F., Pike J.W. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 2003, 278:31756-31765.
58. Hallen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Vaananen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000, 15:1337-1345.
59. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
60. Reszka A.A., Rodan G.A. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003, 5:65-74.
61. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
62. Finkelstein J.S., Hayes A., Hunzelman J.L., Wynland J.J., Lee H., Neer R.M. Effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.